US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

March 9, 2018: By Jon Swedien

The US FDA on March 1 warned health care professionals and patients not to use drug products produced by Cantrell Drug Company of Little Rock, Arkansas.

The American Society of Cataract and Refractive Surgery posted the FDA’s warning on its website.

The FDA said it is concerned about serious deficiencies in Cantrell’s compounding operations, including its processes to ensure quality and sterility assurance that put patient safety at risk.

“Despite the FDA’s concerns about egregious conditions observed at Cantrell’s facility, during several inspections, with the most recent in 2017, the company continued to compound and distribute drugs without adequately addressing their potentially dangerous conditions,” FDA Commissioner Scott Gottlieb said in a press release announcing the warning. “This reckless activity threatens patient safety and will not be tolerated.”

The FDA, with the backing of the Department of Justice, has sought legal action to prevent the company from further producing and distributing drugs, the agency said.

The agency filed a preliminary injunction March 1 in the US District Court in the Eastern District of Arkansas that asked the court to order Cantrell to stop manufacturing, processing, packing, labeling, holding, or distributing any drugs until the company complies with federal law.

The proposed order also will require Cantrell to recall all non-expired drug products on the market, the FDA said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT